-----
NIH Ivermectin|COVID-19 Treatment Guidelines
Last Updated: February 11, 2021

Rationale
Ivermectin has been shown to inhibit the replication of SARS-CoV-2 in cell cultures.
However, pharmacokinetic and pharmacodynamic studies suggest that achieving the plasma concentrations necessary for the antiviral efficacy detected in vitro would require administration of doses up to 100-fold higher than those approved for use in humans.
---
艾弗姆通已被證明能抑制SARS-CoV-2在細胞培養中的複製。
然而，藥動力學和藥理動力學研究表明，要達到體外檢測到的抗病毒功效所需的血漿濃度，需要的劑量比批准用於人類的劑量高100倍。

Clinical Data

Last Updated: July 19, 2021

The Panel has reviewed other clinical studies of IVM for the treatment of COVID-19.1-16 However, those studies have limitations that make them less definitive and informative than the studies discussed here. The studies summarized below are those that have had the greatest impact on the Panel’s recommendations.

專家組審查了 IVM 治療 COVID-19.1-16 的其他臨床研究，但是，這些研究具有局限性，使其不如此處討論的研究具有確定性和信息量。
下面總結的研究是對專家組建議產生最大影響的研究。

Table 2c. Ivermectin: Selected Clinical Data
Table 2c: 各國的實驗與總結